From WCLC 2018

Romero, Diana

doi:10.1038/s41571-018-0109-9

Research Highlight
Published: 02 October 2018

LUNG CANCER

From WCLC 2018

Diana Romero¹

Nature Reviews Clinical Oncology volume 15, page 725 (2018)Cite this article

1111 Accesses
2 Altmetric
Metrics details

Subjects

Access through your institution

Buy or subscribe

The World Conference on Lung Cancer (WCLC) was recently held in Toronto. Three of the studies selected as ‘top 5’ abstracts in this conference were published in the New England Journal of Medicine.

In the PACIFIC trial, the efficacy and safety of durvalumab are being tested in patients with locally advanced, unresectable non-small-cell lung cancer (NSCLC) and good performance status after chemoradiotherapy. An analysis of the second primary end point, overall survival (OS), was presented: 24-month OS was 66.3% and 55.6% with durvalumab and placebo, respectively (P = 0.0025). Grade 3–4 adverse events (AEs) occurred in 30.5% and 26.1% of patients, respectively, leading to treatment discontinuation rates of 15.4% and 9.8%.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

Purchase on SpringerLink
Instant access to full article PDF

Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original articles

Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1809697 (2018)
Article PubMed Google Scholar
Camidge, D. R. et al. Brigatinib versus crizotinib in ALK-positive non–small-cell lung cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1810171 (2018)
Article PubMed Google Scholar
Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1809064 (2018)
Article PubMed Google Scholar

Download references

Author information

Authors and Affiliations

Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc
Diana Romero

Authors

Diana Romero
View author publications
Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Diana Romero.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Romero, D. From WCLC 2018. Nat Rev Clin Oncol 15, 725 (2018). https://doi.org/10.1038/s41571-018-0109-9

Download citation

Published: 02 October 2018
Issue date: December 2018
DOI: https://doi.org/10.1038/s41571-018-0109-9